High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry
Nicolas Mounier(Centre Hospitalier Universitaire de Nice), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Michel Attal(Université Fédérale de Toulouse Midi-Pyrénées), Gordon Cook(University of Leeds), J Maertens(Universitair Ziekenhuis Leuven), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Jan J. Cornelissen(Erasmus MC), Carmen Canals(Hospital de Sant Pau), Christian Gisselbrecht(Institut Universitaire de France), Mats Brune(Sahlgrenska University Hospital), Eulogio Conde(Marqués de Valdecilla University Hospital), Gustaaf W. van Imhoff, Roberto Foà(Sapienza University of Rome), Charles Crawley(Addenbrooke's Hospital), Sébastian Wittnebel(Institut Gustave Roussy), J.J. Luan(Hôpital Claude Huriez), Michael Pfreundschuh(Saarland University)
Cited by 118
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k